Van Leeuwenhoeck Institute has well over 30 years of financial research experience in biotechnology and healthcare between its analysts. 

We are at the forefront of this quickly changing economy and we work closely with our clients because we are fully committed to meeting and exceeding expectations. We also believe in keeping our services affordable to our clients, we make sure to work around your budget.


We are proud that so many of our clients have repeatedly turned to us for guidance and assistance with their financial futures, and we work hard to earn their loyalty every day.


Van Leeuwenhoeck Institute, (“VLI”) is actively engaged in the financial research of life sciences companies in Europe, North America, Australia and emerging markets such as Asia and India.
The team’s sector expertise, combined with an active network of well-respected scientists and biotech business analysts, adds value to VLI’s research.

VLI provides institutional investors and other professional investors with independent, un-biased research on the real value of innovative Life Sciences companies. Many institutional and individual investors will not invest in companies lacking independent third-party research coverage, yet few investment banks cover this sector because it requires dedicated expertise. In spite of the lack of quality knowledge on an industry-wide basis, there is increased demand for life science-specific market research as investors are seeking information about leading companies in the sector in order to make well-informed investment decisions.

A subscription service provides detailed information on a wide selection of biotech companies that investors are tracking. This service is based on quarterly, in-depth research reports and a daily email service to keep subscribers informed about relevant news flow and issues that might trigger fluctuations in the price of the underlying securities.

The VLI team conducts fundamental financial research, independently from any specific broker, bank, or investor. A select circle of top analysts assists the firm in conducting fundamental biotech research according to the highest standards.

Investment banking firms, institutions, and individual investors retain VLI to obtain independent company equity research. The firm's research operations are similar to a research department of a major investment banking firm but without brokerage or investment banking operations. Unlike traditional brokerage firms that limit research distribution to clients in exchange for commissions, VLI widely distributes its research to institutions and individuals within Europe and North America.

 

INDEPENDENT QUALITY 

Experience